Primary prevention of beta-cell autoimmunity and type 1 diabetes – The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) perspectives

201664 citationsReviewgold Open Access

Authors

AG Ziegler · TUM Klinikum

Thomas Danne · Kinderkrankenhaus auf der Bult

David B. Dunger · University of Cambridge

Reinhard Berner · University Hospital Carl Gustav Carus

Ramona Puff · TUM Klinikum

W. Kiess · University Hospital Leipzig

Gina Agiostratidou · Leona M. and Harry B. Helmsley Charitable Trust

Abstract

It is timely and feasible to establish a platform for primary prevention trials for type 1 diabetes in Europe. This multi-site European infrastructure would perform RCTs, supply data coordination and biorepository, provide cohorts for mechanistic and observational studies, and increase awareness for autoimmune diabetes.

Topics & Keywords

Diabetes and associated disorders Diabetes Management and Research Pancreatic function and diabetes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Molecular Metabolism

Volume 5, Issue 4, pp. 255-262

DOI: 10.1016/j.molmet.2016.02.003

Field-Weighted Citation Impact: 7.50